Safe for Passengers with Lung Disease to Travel by Air

According to two articles published in the Wiley-Blackwell journal, Respirology, commercial air travel appears to be safe for patients with lung disease as the current policies for the in-flight oxygen levels and availability of supplemental oxygen can adequately accommodate passenger’s needs.

The paper entitled, “Predicting the response to air travel in passengers with non-obstructive lung disease: Are the current guidelines appropriate?” quantified the hypoxaemic, or the blood oxygenation level, response in 14 patients with non-obstructive lung disease during air travel and compares it to the British Thoracic Society (BTS) air travel published guidelines.

“The BTS guideline uses common diagnostic tools to provide a simple oxygen level algorithm to identify patients who may require in-flight oxygen. By using the BTS recommendations, we are able to identify the subjects that needed supplement oxygen during the flight. These findings should add confidence to passengers with pulmonary disorders wishing to travel”, said co-author Dr. Paul Kelly from the Respiratory Physiology Laboratory at Christchurch Hospital.

Another paper in the issue, “Airline policy for passengers requiring supplemental in-flight oxygen” examines 54 commercial airlines servicing Australia and New Zealand to consolidate information on the current airline policies on supplemental in-flight oxygen for passengers with lung disease, as well as its approximate cost to passengers.

While the study confirmed that most airlines can accommodate passengers requiring supplemental oxygen, there was substantial variation in air policies and cost for passengers with lung disease who wish to travel while using supplemental oxygen.

Co-author, Dr. Lutz Beckert, from the Christchurch School of Medicine, University of Otago said, “Passengers with lung disease can use this study as a resource to compare airline policies and find a carrier that best suits their needs. In addition, these findings may also act as a catalyst for air travel providers to consider the development of a standard policy for the industry.”

_____________________________________________________________
These articles are published in the May issue of Respirology (Vol. 14, Issue 4).
Media wishing to receive a PDF or schedule media interviews with the authors should contact Alina Boey, Senior Manager, Corporate Communications at aboey@wiley.com or phone 65-96565580.

The abstract of “Predicting the response to air travel in passengers with non-obstructive lung disease: Are the current guidelines appropriate?” is available at: http://www3.interscience.wiley.com/journal/122304815/abstract

The abstract of “Airline policy for passengers requiring supplemental in-slight oxygen” is available at: http://www3.interscience.wiley.com/journal/122304816/abstract

About Respirology
Respirology is a journal of international standing, publishing peer-reviewed articles of scientific excellence in clinical and experimental respiratory biology and disease and its related fields of research including thoracic surgery, internal medicine, immunology, intensive and critical care, epidemiology, cell and molecular biology, pathology, pharmacology and physiology.

About Wiley
Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for 200 years, helping people around the world meet their needs and fulfill their aspirations. Since 1901, Wiley and its acquired companies have published the works of more than 350 Nobel laureates in all categories: Literature, Economics, Physiology/Medicine, Chemistry and Peace.
Our core businesses include scientific, technical, medical and scholarly journals, encyclopedias, books, and online products and services; professional/trade publishes books, subscription products, training materials, and online applications and websites; and educational materials for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company’s Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.

About Wiley-Blackwell
Wiley-Blackwell is the international scientific, technical, medical and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world’s leading societies. Wiley-Blackwell publishes over 1,400 peer-reviewed journals as well as 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or http:// www.interscience.wiley.com.